BLK vs NVO Comparison

BlackRock is the largest asset manager in the world, with $15.345 trillion in assets under management at the end of June 2026. Its product mix is diverse, with 58% of managed assets in equity strategies, 22% in fixed income, 9% in multi-asset classes, 7% in money market funds, and 4% in alternatives. Passive strategies account for two-thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which, by our calculations, account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one-third of managed assets coming from investors domiciled outside the US and Canada.

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.